文献速递其他结缔组织病

原发性干燥综合征中全身I型和II型干扰素特征揭示生物学疾病活动度的差异

Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

研究通过全血RNA的RT-PCR和主成分分析,在50例原发性干燥综合征患者中识别全身IFN-I和IFN-II活动的指示基因,并在两个独立欧洲队列(n=86和55)中分析其与临床特征的关系。结果显示全身IFN激活仅与ESSDAI生物学领域评分较高相关,而与其他领域或总分无关。

要点

  • 全身IFN激活仅与ESSDAI生物学领域评分较高相关,与ESSDAI总分或其他领域无关。
  • 未发现孤立性IFN-II激活的患者,患者可分为IFN不活跃、IFN-I和IFN-I+II三组。
  • 作者认为ESSDAI生物学领域评分可能是针对IFN通路试验的更敏感终点。

核心结论

  • 全身IFN激活仅与ESSDAI生物学领域活动度较高相关,与其他领域或总分无关。
  • 作者认为ESSDAI生物学领域评分可能是针对IFN通路试验的更敏感终点。

研究设计与样本

  • 对50例原发性干燥综合征患者全血RNA进行多个IFN诱导基因的RT-PCR和主成分分析,以识别全身IFN-I和IFN-II活动的指示基因。
  • 在两个独立欧洲队列(分别为n=86和n=55)中分析全身IFN激活水平及其与临床特征的关系。

主要发现

  • 根据全身IFN活动可分为三组:IFN不活跃(19-47%)、IFN-I(53-81%)和IFN-I+II(35-55%)。
  • 无患者表现为孤立性IFN-II激活。
  • IgG水平在IFN-I+II组最高,其次为IFN-I组和IFN不活跃组。
  • 抗SSA和抗SSB的患病率在IFN激活者中更高。
  • 三组间总EULAR干燥综合征疾病活动指数(ESSDAI)或ClinESSDAI无差异;单个ESSDAI领域中仅生物学领域评分在三组间有差异(IFN激活组更高)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the relationships between systemic IFN type I (IFN-I) and II (IFN-II) activity and disease manifestations in primary SS (pSS). METHODS: RT-PCR of multiple IFN-induced genes followed by principal component analysis of whole blood RNA of 50 pSS patients was used to identify indicator genes of systemic IFN-I and IFN-II activities. Systemic IFN activation levels were analysed in two independent European cohorts (n = 86 and 55, respectively) and their relationships with clinical features were analysed. RESULTS: Three groups could be stratified according to systemic IFN activity: IFN inactive (19-47%), IFN-I (53-81%) and IFN-I + II (35-55%). No patient had isolated IFN-II activation. IgG levels were highest in patients with IFN-I + II, followed by IFN-I and IFN inactive patients. The prevalence of anti-SSA and anti-SSB was higher among those with IFN activation. There was no difference in total-EULAR SS Disease Activity Index (ESSDAI) or ClinESSDAI between the three subject groups. For individual ESSDAI domains, only the biological domain scores differed between the three groups (higher among the IFN active groups). For patient reported outcomes, there were no differences in EULAR Sjögren's syndrome patient reported index (ESSPRI), fatigue or dryness between groups, but pain scores were lower in the IFN active groups. Systemic IFN-I but not IFN-I + II activity appeared to be relatively stable over time. CONCLUSIONS: Systemic IFN activation is associated with higher activity only in the ESSDAI biological domain but not in other domains or the total score. Our data raise the possibility that the ESSDAI biological domain score may be a more sensitive endpoint for trials targeting either IFN pathway.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, et al. Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity. Rheumatology (Oxford). 2018. PMID: 29474655. doi:10.1093/rheumatology/kex490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。